Meeting
2023 ASCO Genitourinary Cancers Symposium
BMX inhibition and HSD3B1-driven resistance in prostate cancer in the Maverick trial.
Authors
Nima Sharifi
GU Malignancies Research Center, Cleveland Clinic, Cleveland, OH
Nima Sharifi , Rana R. McKay , Jake Vinson , Mike A. Royal , Joshua Michael Lang , Eric A. Klein , Xiuxiu Li , Michael Berk , Christopher Goins , Mohammad Alyamani , Yoon-Mi Chung , Chenyao Wang , Mona Patel , Nityam Rathi , Ziqi Zhu , Belinda Willard , Shaun Stauffer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05361915
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 144)
DOI
10.1200/JCO.2023.41.6_suppl.144
Abstract #
144
Poster Bd #
E5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
First Author: Rana R. McKay
Poster
2018 Genitourinary Cancers Symposium
Niclosamide in combination with abiraterone and prednisone in men with castration-resistant prostate cancer (CRPC): initial results from a phase Ib/II trial.
First Author: Chong-xian Pan
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
First Author: Evan Y. Yu
Poster
2018 Genitourinary Cancers Symposium
A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC).
First Author: Chong-xian Pan